NCT04991103 2025-12-31Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)University of Alabama at BirminghamPhase 2 Recruiting40 enrolled
NCT03201965 2025-11-26A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) AmyloidosisJanssen Research & Development, LLCPhase 3 Completed416 enrolled 28 charts 5 FDA